EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinic...( Selective Kinase Inhibitor Phase ...),Health

Selective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients

ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1, dose-escalation study for its selective kinase inhibitor, ENMD-2076, in advanced cancer patients. Dr. Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigator for the study. Additional centers are expected to join Colorado as study sites this quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular toxicity.

The Phase 1 study will assess safety and tolerability of orally administered ENMD-2076 in refractory cancer patients. In addition, pharmacokinetics will be assessed to determine a dose-dependent response to treatment with ENMD-2076.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the study, "Commencement of this
'/>"/>